title: [Aflibercept: focus on tolerability.]
abstract: Aflibercept, a potent antiangiogenic agent that exhibits a broad spectrum of antitumor activity, is currently administered in combination with FOLFIRI for the second-line treatment of metastatic colorectal cancer. Here, practical measures to minimize the risk of toxicity in real-world patients are suggested.
authors.affiliation: UO di Oncologia, Fondazione Poliambulanza, Brescia.
authors.forename: Alberto
authors.initials: A
authors.lastname: Zaniboni
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D002166:Camptothecin; D015179:Colorectal Neoplasms; D005472:Fluorouracil; D006801:Humans; D002955:Leucovorin; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin